RUIHE DATA (03680) announced its interim results, with profit attributable to shareholders of 58.205 million yuan, a year-on-year increase of 34.78%.
Ruihe Shuzhi (03680) announced its performance for the six months ended June 30, 2026, reporting revenue of 94.46 million yuan, a year-on-year decrease of 19.88%; profit attributable to shareholders was 58.205 million yuan, a year-on-year increase of 34.78%; earnings per share were 6.65 cents.
RUIHE DATA (03680) announced its results for the six months ending June 30, 2026, reporting revenue of 94.46 million yuan, a year-on-year decrease of 19.88%. The profit attributable to owners of the company was 58.205 million yuan, a year-on-year increase of 34.78%. Earnings per share were 6.65 cents.
The primary reasons for the increase in profit during the reporting period are as follows: the group's share of profit from joint ventures was approximately 11.843 million yuan, mainly derived from the group's joint venture Shenzhen Jichuang. In the first half of 2025, the group did not report any share of profits from joint ventures. The group actively promoted cost reduction and efficiency improvement measures during the reporting period, resulting in a decrease of approximately 4.148 million yuan in employee benefit expenses and approximately 7.668 million yuan in depreciation and amortization expenses; however, these were partially offset by a decrease in gross profit of approximately 2.987 million yuan and an increase of approximately 5.559 million yuan in expected credit losses on financial and contract assets. Overall, these combined effects resulted in an operating loss that was approximately 3.243 million yuan narrower than the same period in 2025.
Related Articles

Shanghai RAAS Blood Products (002252.SZ): The SR604 injection is proposed to be included in the Care Program - Extension pilot project.

After a ten-week hiatus, Strategy (MSTR.US) has restarted buying, investing $370 million to increase its holdings in Bitcoin.

HIGHTIDE-B (02511) announced its interim results, reporting a loss attributable to shareholders of approximately 146 million yuan, a year-on-year increase of 21.43%.
Shanghai RAAS Blood Products (002252.SZ): The SR604 injection is proposed to be included in the Care Program - Extension pilot project.

After a ten-week hiatus, Strategy (MSTR.US) has restarted buying, investing $370 million to increase its holdings in Bitcoin.

HIGHTIDE-B (02511) announced its interim results, reporting a loss attributable to shareholders of approximately 146 million yuan, a year-on-year increase of 21.43%.

RECOMMEND





